Cipla to divest animal health business in South Africa, Sub-Saharan Africa

06 Mar 2017 Evaluate

Cipla has entered into agreements, through its wholly owned subsidiary Inyanga Trading 386 Proprietary (Inyanga), with the group companies of Ascendis Health, South Africa for divesting its animal health business in South Africa and Sub-Saharan Africa.

Under the agreements, Cipla will divest its 100% stake in Cipla Agrimed Proprietary (Cipla Agrimed), South Africa and Cipla Vet Proprietary (Cipla Vet), South Africa. The total consideration of transaction would be ZAR 375 million with potential revision linked to FY2017 performance along with customary adjustment (within the price band of R250m and R500m) in relation working capital and net debt/cash adjustments. The deal is subject to customary closing conditions including approval from competition commission of South Africa and is expected to close in the next 3 months.

Cipla Agrimed operates in the farm animals segment, with sales mainly attributable to agricultural co-operatives and bulk farm purchasing organizations. Cipla Agrimed has a leading position in antimicrobials and endectocides in South Africa.

Cipla Vet operates in the companion animal segment with sales primarily to wholesalers. Cipla Vet has a strong presence in the South African market, with leading positions in Proton Pump Inhibitors, Non-steroidal Anti-inflammatory Drugs (NSAIDs) and supplements.



Cipla Share Price

1345.35 -2.30 (-0.17%)
19-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1525.00
Dr. Reddys Lab 5942.65
Cipla 1345.35
Zydus Lifesciences 925.95
Lupin 1547.05
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.